SOURCE: TomoTherapy


October 27, 2009 09:00 ET

TomoTherapy Names Recipients of 2009-2010 Clinical Investigation Grants

Partnership Program Provides Research Support to TomoTherapy® Users

MADISON, WI--(Marketwire - October 27, 2009) - TomoTherapy Incorporated (NASDAQ: TOMO) today announced four recipients of grants from the first round of its 2009-2010 TomoTherapy® Clinical Investigation Partnership Program. The program supports research on the clinical benefits of intensity-modulated radiation therapy (IMRT) and image-guided radiation therapy (IGRT) for improving cancer care.

"TomoTherapy users around the globe are demonstrating how technological advances in radiation therapy are giving patients new hope in battling cancer," said Gustavo Olivera, Ph.D., vice president of Research at TomoTherapy. "With the grants we are providing as part of the Clinical Investigation Partnership Program, TomoTherapy is underscoring its commitment to further cancer research, and we look forward to seeing the results of our recipients' work."

This year's grant recipients include:

City of Hope Cancer Center, Duarte, Calif. -- Total Marrow Irradiation

Correlating Organ Dose and Dose-Volume with Toxicities After Total Marrow Irradiation (TMI) in Patients Undergoing Hematopoietic Cell Transplantation (HCT)

Led by Jeffrey Wong, M.D., FASTRO, this study is designed to further characterize the effectiveness of total marrow irradiation (TMI), comparing toxicities to various organs with those of traditional total body irradiation (TBI). TMI dose data for various organs will be analyzed and used to evaluate the possibility of future dose escalation aimed at further increasing the effectiveness of treatment without increasing rates of toxicity.

"The TomoTherapy Hi·Art® treatment system is groundbreaking technology that allows us to deliver a much more targeted form of TBI in patients undergoing bone marrow transplantation, a potentially lifesaving procedure," said Dr. Wong, chair of the Department of Radiation Oncology at City of Hope. "At the City of Hope, dozens of patients have already undergone this treatment, which has resulted in fewer side effects. It also has given us the ability to offer this approach to older patients, something that was not possible in the past. This research grant gives us the necessary resources to continue to monitor side effects on a longer-term basis. Results from this project will help better quantify any long-term side effects related to therapies that will help refine TomoTherapy targeted TBI-approaches in the future."

London Regional Cancer Program (LRCP), London, Ontario, Canada -- Brain Tumors

A Phase II Multi-institutional Study Assessing Simultaneous In-field Boost Helical TomoTherapy for 1-3 Brain Metastases (TC2-01)

Led by George Rodrigues, M.D., this clinical trial will evaluate use of helical TomoTherapy for delivering a simultaneous in-field boost (SIB) treatment to one to three brain metastases along with whole brain irradiation, comparing local control rates to those treated with whole brain irradiation (WBI) and subsequent conventional stereotactic radiosurgery (SRS). A further multi-institutional study will follow to assess overall survival, tumor control and treatment toxicity.

"As one of the first users of TomoTherapy, LRCP has a wealth of experience using the technology," said Dr. Rodrigues, a clinician scientist with LRCP/London Health Sciences Centre and the University of Western Ontario. "With this grant, we look forward to learning more about how we can effectively leverage the technology to deliver SIB radiotherapy with the IMRT and IGRT capabilities of the machine."

University of Heidelberg, Germany -- Lung Cancer

Pleural Mesothelioma Adjuvant treatment with TomoTherapy (PLATO)

Led by the University's Department of Radiation Oncology under Klaus Herfarth, M.D., this study will examine whether treatment of malignant pleural mesothelioma with helical TomoTherapy can reduce the radiation dose to the non-diseased lung, potentially decreasing overall toxicity, enabling delivery of higher doses to further reduce recurrence rates.

"We are constantly seeking ways to improve patient treatments, and the TomoTherapy system has given us the chance to offer patients with pleural mesothelioma a safe and sufficient radiation therapy in a multidisciplinary approach," said Dr. Herfarth, vice chairman of the Department of Radiation Therapy at the University of Heidelberg. "We believe the PLATO trial will prove the safety and efficacy of TomoTherapy in this setting and we are very grateful for the support of the Clinical Investigation Partnership Program to help us to organize and to execute this trial."

University of Wisconsin Carbone Cancer Center/Wisconsin Oncology Network -- Lung Cancer

A Phase II Study Utilizing Helical TomoTherapy and Adaptive Image Guided TomoTherapy with Chemotherapy for Small Cell Lung Cancer to Reduce Toxicity

Led by Deepak Khuntia, M.D., this trial will investigate whether TomoTherapy can enable a more aggressive chemo-radiotherapy scheme for the treatment of small cell lung cancer. The study will focus on the rate of toxicity to the esophagus and lungs during the first 120 days after the start of treatment, as well as whether adaptive re-planning, after re-defining tumor volume half way through the course of treatment can further reduce toxicity.

"We are in the early stages of understanding how adaptive radiation therapy using IGRT can be effective in treating patients who have tumors that change rapidly," said Dr. Khuntia, associate professor of Human Oncology at the University of Wisconsin Carbone Cancer Center. "This grant will enable us to apply modern technology in a multi-institutional setting, in the hope of improving cancer care with new treatment protocols."

The TomoTherapy Clinical Investigation Partnership Program was introduced in March 2009. Applications for the second round of 2009-2010 grants are currently being accepted. All TomoTherapy technology users are eligible for consideration.

About TomoTherapy Incorporated
TomoTherapy Incorporated has developed, markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy® platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue.

TomoTherapy's suite of solutions include its flagship Hi·Art® treatment system, which has been used to deliver more three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD™ treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile™ relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care.

TomoTherapy's stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit

Forward-Looking Statements
Statements in this release regarding research, expectations, future products and other similar matters, including but not limited to statements using the terms "believe(s)", "will", "can", "expect", or "should" constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements contained in this press release are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated, including but not limited to factors such as our ability to gain customer acceptance, ability to complete development in a timely manner, ability to protect intellectual property, risks of interruption due to events beyond the company's control, and the other risks listed from time to time in TomoTherapy's filings with the U.S. Securities and Exchange Commission, which by this reference are incorporated herein. These forward-looking statements represent TomoTherapy's judgments as of the date of this press release. TomoTherapy assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events or otherwise.

©2009 TomoTherapy Incorporated. All rights reserved. The following marks as used herein in italicized or stylized text are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated in the United States and other countries: TomoTherapy, Tomo, TomoDirect, TomoHelical, TomoHD, TomoMobile, TQA, Hi·Art, and the TomoTherapy logo.

Contact Information

  • Investor Contact:
    Thomas E. Powell
    Chief Financial Officer
    Email Contact

    Media Contacts:
    Kevin O'Malley
    Manager, Corporate Communications
    Email Contact

    Susan Lehman
    Rockpoint Public Relations
    Email Contact